PRTA News and Press, Prothena Corporation plc From 11/06/25

2025-11-06 16:10:29 ET More on Prothena Seeking Alpha’s Quant Rating on Prothena Historical earnings data for Prothena Financial information for Prothena Read the full article on Seeking Alpha For further details see: Prothena GAAP EPS of -...

Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million Roche to initiate the Phase 3 PARAISO clinical trial evaluating prasinez...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2025 financial results on Thursday No...

2025-10-01 17:17:39 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript Bristol Myers Squibb: Buy This Deep Bargain Before The Market Wakes To In...

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the potential of anti-MTBR tau to be an important treatment option for patients with Alzheimer’s disease ...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Cantor Fitzger...

As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibody Phase 1 ASCENT clinical program established proof-of-mechanism for PRX012 as a once-monthly, subcutaneous anti-amyloid beta...

2025-08-06 10:03:06 ET More on Novo Nordisk, Prothena GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly Novo Nordisk Is Now A Better Value Play Than Eli Lilly With Solid Upside Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Lik...

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to initiate a Phase 3 program in 2025 Prothena to earn a clinical mileston...